Back to 
JPMorgan Chase & Co.
JPMorgan Chase & Co.
IKT
5 quarters
Position history for JPMorgan Chase & Co.'s holdings in Inhibikase Therapeutics, Inc.
Yes. JPMorgan Chase holds 316,574 shares of IKT (Inhibikase Therapeutics), worth $610,988, as of its Q2 2026 13F filing. It reduced the position by 11,944 shares (-3.6%) from Q1 2026. JPMorgan Chase has held IKT since Q2 2025, across 5 quarterly 13F filings.
Current Value
$610,988
Current Shares
316,574
Total Value Change
+$555,259
Total Shares Change
+287,995
Quarter-by-Quarter History
Other major holders of IKT: BlackRock, Inc., Blackstone Inc., Vanguard Capital Management LLC